Apreo Health

Apreo Health is a clinical-stage medical device company located in Menlo Park, California. The company focuses on developing innovative, tissue-sparing treatments for severe emphysema, a serious pulmonary disease. Apreo Health aims to redefine interventional pulmonology by offering a novel, non-destructive therapy that expands patient access and simplifies treatment delivery. The flagship product, the BREATHE Airway Scaffold, is a first-of-its-kind implant that is delivered bronchoscopically into the lungs. This device helps relieve lung hyperinflation by allowing trapped air to escape without damaging healthy lung tissue. The BREATHE Airway Scaffold has received breakthrough device designation from the U.S. FDA and is currently undergoing pivotal clinical trials, including the BREATHE-3 study. Apreo Health is supported by significant venture funding, including a $130 million Series B round, which will be used for clinical trials and regulatory approvals. The company is dedicated to serving patients with severe emphysema, a group that currently has limited treatment options. Apreo Health emphasizes regulatory compliance and data protection as it prepares for clinical trial rollouts in the U.S. and Europe.

• Employees 22